New cholesterol-lowering treatment is more flexible and effective

Credit: Unsplash+

A groundbreaking cholesterol-lowering treatment, known as recaticimab, has shown promise in a recent study presented at the American Heart Association’s Scientific Sessions 2023.

This innovative therapy, which can be administered every one to three months, aims to provide a safer and more adaptable approach to managing cholesterol levels.

High cholesterol is a significant risk factor for heart disease, which is a leading cause of death worldwide. When cholesterol levels are too high, it can lead to dangerous blockages in the arteries, increasing the risk of heart attacks and strokes.

To combat this, cholesterol-lowering medications, such as statins, have been widely used. However, some individuals do not respond well to these drugs or experience side effects.

The Role of PCSK9 Inhibitors

PCSK9 inhibitors are a type of medication that helps lower cholesterol levels by blocking a specific protein in the liver.

This protein, PCSK9, plays a role in regulating cholesterol in the body. By inhibiting PCSK9, these medications can effectively reduce bad cholesterol (LDL) levels in the blood.

Flexible Cholesterol Management

The study explored the potential benefits of recaticimab, a new PCSK9 inhibitor, for individuals with high cholesterol.

What makes recaticimab unique is that it offers a more flexible dosing schedule, with injections required only every one to three months. This flexibility may increase patient adherence and improve cholesterol management.

Key Findings

The research involved 689 participants who had persistently high cholesterol levels, despite taking statin medications. They were divided into three groups:

  1. One group received recaticimab injections every four weeks.
  2. Another group received injections every eight weeks.
  3. The third group received injections every 12 weeks.

The results were promising:

  • Recaticimab effectively reduced bad cholesterol levels in all dosing groups.
  • Participants in the recaticimab groups reached their cholesterol targets by 24 weeks, and these levels were maintained at 48 weeks.
  • Injection site reactions were similar in both the recaticimab and placebo groups.


Recaticimab’s effectiveness and flexibility suggest that it may become a valuable tool in managing cholesterol levels. Patients and healthcare providers could have more options for tailoring treatment to individual needs.

Looking Ahead: The study’s secondary findings also indicated positive effects on other risk factors for heart disease, such as lipoprotein(a) and apolipoprotein B. Further research will explore the potential cardiovascular benefits of recaticimab.


Recaticimab, a novel cholesterol-lowering treatment with a flexible dosing schedule, has shown promising results in reducing bad cholesterol levels.

This therapy offers hope for individuals struggling with high cholesterol, potentially leading to better heart health outcomes. Further studies will explore its broader benefits and applicability.

If you care about heart health, please read studies about Scientists find a new cause of heart rhythm disorders and findings of Eating just one cup of nitrate-rich vegetables daily can reduce heart disease risk.

For more information about cholesterol levels., please see recent studies about A review of plant-based diets for lowering cholesterol and results showing that Unlocking the power of food to lower cholesterol.

Follow us on Twitter for more articles about this topic.

Copyright © 2023 Knowridge Science Report. All rights reserved.